Post Hoc Analysis of MRD Negativity After End of Induction in the Phase 3 PhALLCON Trial
Por:
Aldoss, I, Vachhani, P, Kantarjian, H, Montesinos, P, Leonard, J, Gomez-Almaguer, D, Baer, MR, Gambacorti-Passerini, C, Mccloskey, J, Minami, Y, Papayannidis, C, Rocha, V, Rousselot, P, Wang, ENC, Hennessy, M, Vorog, A, Patel, N, Santasusana, JMR and Jabbour, E
Publicada:
1 sep 2025
Resumen:
Filiaciones:
Aldoss, I:
City Hope Duarte, Duarte, CA USA
Vachhani, P:
Univ Alabama Birmingham, Birmingham, AL USA
Kantarjian, H:
Univ Texas MD Anderson Canc Ctr, Houston, TX USA
Montesinos, P:
Hosp Univ & Politecn La Fe Valencia, Valencia, Spain
Leonard, J:
Oregon Hlth & Sci Univ, Portland, OR USA
Gomez-Almaguer, D:
UANL, Hosp Univ, Monterrey, Mexico
Baer, MR:
Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA
Gambacorti-Passerini, C:
Univ Milano Bicocca, Monza, Italy
Mccloskey, J:
Hackensack Univ, Med Ctr, Hackensack, NJ USA
Minami, Y:
Natl Canc Ctr Hosp East, Kashiwa, Japan
Papayannidis, C:
IRCCS Azienda Osped Univ Bologna Ist Ematol Seragn, Bologna, Italy
Rocha, V:
Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
Rousselot, P:
Hosp Mignot Univ Versailles St Quentin En Yvelines, Paris, France
Wang, ENC:
Roswell Pk Comprehens Canc Ctr, Leukemia Serv, Buffalo, NY USA
Hennessy, M:
Takeda Dev Ctr Amer Inc, Cambridge, MA USA
Vorog, A:
Takeda Dev Ctr Amer Inc, Cambridge, MA USA
Patel, N:
Takeda Dev Ctr Amer Inc, Cambridge, MA USA
:
ICO Hosp Germans Trias & Pujol, Barcelona, Spain
Jabbour, E:
Univ Texas MD Anderson Canc Ctr, Houston, TX USA
|